41 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
Chung, President and Chief Operating Officer at Sutro. “Sutro’s research innovation represented in STRO-003 illustrates our leadership in ADC design
8-K
EX-99.1
STRO
Sutro Biopharma Inc
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.
Corporate Updates:
Sutro continues to build a world-class leadership
8-K
EX-99.1
f4n2nv7d8
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
rg8q9ypqj7
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
3p5 74qlip
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
29hur kx94e9c7c5u
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
gtvtre nulnk
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
iepa5jsbchpo9
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
fk13hepfpd4slngbc h0
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm